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The exclusion criteria used in some of the trials are also likely to introduce an element of bias. For example, nine of these trials excluded patients with suspected ureteral mucosal perforation during their operation and routinely stented these patients instead.
Outcome measures assessed by Pengfei and colleagues 2 included mean operative time, lower urinary tract symptoms, fever, infection, pain (including need for analgesia), unplanned rehospitalization, and stent-related complications. However, these measures are difficult to contextual ize without further characterization of the study groups. For example, specific stone-related parameters seen on radiologic imaging (such as stone size, hydro nephrosis, and suspected obstruction) are not noted, and factors such as patient comorbidity, the nature of the surgical procedure and technique, antibiotic regimens, and the duration of post procedural hospitaliza tion are not clearly delineated. The authors state that reducing the risk of bias by blinding is "not suitable" for surgical trials, which is a misleading oversimplification. Only the surgeon cannot be blinded; other individuals involved in the study can be, with outcome assessors being a notable example. 3 Importantly, the authors never actually define "uncomplicated uretero scopy", resulting in some ambiguity over which patients might be included in this category. For example, would the use of ureteral stenting following shockwave litho tripsy for large calculi-which has been shown to reduce rates of steinstrasse 4 and rehospitalization 5 -be considered as "complicated"? In the case of ureteroscopy for ureteral stones, it remains unclear what constitutes a "complicated" or "uncomplicated" procedure, although it is likely that determining factors would relate to the calculus and its associated manifestations, as well as the specific nature of the surgical procedure.
MacDonald et al. 6 recently assessed the methodological quality of systematic reviews published within the field of urology from 1998 to 2008. They found that an increasing number of urological reviews fail to meet established standards, raising questions over their validity. Shea et al. 7 developed a measurement tool called AMSTAR that assesses the methodological quality of systematic reviews. Using AMSTAR to analyze the meta-analysis by Pengfei et al. 2 highlights a number of deficiencies: lack of an a priori protocol; no search for unpublished studies or gray literature; an incomplete description of study characteristics; unreported quality assessment results; potential (untested) publica tion bias; and no discussion of conflict of interests. In light of this, it is difficult to have confidence in the results of this report. As an example, the difference in rates of readmission and rehospitalization for stented versus nonstented patients is deemed to be insignificant by the authors, but the confidence interval is very wide (0.71-1.96)-likely reflecting the rarity of this event-and the study is underpowered to make this claim.
If the issue of whether to stent patients after ureteral stone lithotripsy is to be properly clarified, it is imperative that the study population is representative of the wider population intended for treatment. Indeed, a large shortcoming of this meta-analysis is that it is not entirely clear how the study population was constituted. Explicit inclusion and exclusion criteria are of critical importance in studies such as these, as outcomes could affect urologists' decision making. In summary, what the authors conclude using limited study parameters may be true, but it is doubtful that urologists would change their practice based on this particular study. Lost in transition, losing money, but caution precludes a "quick fix"
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Cancer survivors represent a burgeoning patient population at risk of recurrence and comorbidity. Their needs are great and we must find ways to deliver care that optimizes health, without "breaking the bank. " Fragmentation of care contributes to higher health-care costs, so strategies that reduce redundancy while preserving quality of care are essential. In a recent report investigating the fragmenta tion of prostate cancer survivorship care, Skolarus, Zhang and Hollenbeck relayed results of a study that included 66,736 Medicare patients diagnosed with prostate cancer. 1 Their defined purpose was to quantify the level of fragmentation of care in this patient population and to assess the degree to which increased fragmentation led to greater health-care costs and poorer quality of care. NATURE REVIEWS | UROLOGY VOLUME 9 | JANUARY 2012 | 15
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Prostate cancer survivors represent the second-largest segment of cancer survivors in the USA-surpassed only by breast cancer survivors-and currently number over 2 million.
2 Health-care needs are great among men with prostate cancer, and so are the associated costs, which total nearly $7 billion per year. 3 In this large sample of men, who were tracked from 1992 to 2005, Skolarus et al. 1 defined "survivorship" as the period extending from 1 year after the patient's diagnosis to 2005, or to the year before death. This period was chosen based on the assumption that by 1 year after diagnosis, treatment should be complete and patterns of care stable. Researchers character ized fragmenta tion of care using a composite measure that factored in the average number of health-care providers and intensity of care across providers, ultimately grouping men into three categories: low, inter mediate, or high fragmentation. The primary finding was that care was most highly fragmented among younger, white men of higher socioeconomic status. Furthermore, as compared to low fragmenta tion, high fragmentation of care was associated with significantly greater annual per capita health-care expenditures, of US$142 versus US$453, respectively (P <0.001). Men who were classified as having high fragmentation of care also had significantly lower quality of care (defined as redundant PSA testing within a 30-day period; P <0.001). Redundant testing was performed on 14.7% of men in the highly fragmented care group, compared with 5.7% in the low-fragmented care group. Costs were lower among men who received androgen deprivation therapy (ADT), as compared to other treatment-likely because of the absence of locoregional treatment and reduction in associated adverse effects.
Concerns regarding fragmentation of care were addressed over a decade ago, when the Institute of Medicine (IOM) Committee on Quality of Health Care in America, 4 called for care based on continuous healing relation ships, continuous decrease in waste, and co-operation among clinicians. Given that cancer survivors are often treated by at least five physicians, and there is increased risk of fragmentation of care in these patients, 5 these tenets were reiterated in the 2005 IOM report, From Cancer Patient to Cancer Survivor: Lost in Transition. 6 This hallmark document also chronicled the late and long-term effects of cancer and its treatment, as well as the high rates of comorbidity in this patient population. 5 Prostate cancer poses a particular challenge in evaluating the quality of survivorship care, and the fact that Skolarus et al. 1 chose to chronicle fragmentation in this particular cancer is certainly ambitious. Firstly, treatment options for prostate cancer range from conservative options, such as active surveillance, to active treatments, such as surgery or radiotherapy. Each of these options is likely to be delivered by a different provider. Moreover, a patient might choose to remain under active surveillance for the rest of his life or only until the anxiety associated with PSA monitoring exceeds his distaste for more definitive treatment-a process that might take years and can perpetuate fragmentation of care in the long term. In addition, many treatments have adverse effects on the urinary system and bowels, as well as causing erectile dysfunction, and the time course of these adverse effects depends on the treatment, with some occurring immediately and others being substantially delayed until some time after treatment has been completed. The remedies for adverse effects associated with prostate cancer treatment are typically not "quick fixes" and often involve extended consulta tion to address all of the contributing issues-both physio logical and psycho logical-all of which further contribute to the long-term fragmentation of care. Finally, fragmentation is increased because prostate cancer is a disease of older men who often have comorbidi ties that pose a more urgent threat to their survival than their prostate cancer and that, therefore, require the input of multiple subspecialists and primary-care physicians. Thus, it is unsurprising that Skolarus et al. 1 found that 63.4% of prostate cancer survivors receive care that is either intermediate or highly fragmented. Another predictable finding is that younger men receive more costly and more fragmented care-probably because they are more likely to receive more aggressive treatments, resulting in a wider range and greater severity of associated adverse effects. Another unsurprising finding relates to the fact that men treated with primary ADT receive less fragmented care, owing to the reduced likelihood of adverse effects associated with surgery or radiotherapy Thus, although the data that Skolarus et al. 1 provide regarding fragmentation of care and cost for prostate cancer survivors is informative and logical, it is not necessarily actionable. Their article places particular value on a 'one patient-one physician' model to reduce fragmentation. However, the complexity of prostate cancer, its treatment (and attendant adverse effects) and late sequelae mean that, although fragmenta tion of care could be reduced by restricting the number of involved physicians, this might not be possible or, indeed, desirable, particularly for managing lingering effects of treatment that require specialized care. Certainly, as time elapses from diagnosis, the responsibility of caring for prostate cancer patients should shift towards primary-care physicians who may best address their overall health-care needs, and away from the urologist. 5 This care strategy is most applicable to men with locoregional disease, who are far more likely to die of causes other than prostate cancer. However, the premise that fragmentation of care can be solved by reducing the number of providers after a set period of time postdiagnosis is very likely untenable.
It is through improved communication that we are most likely to optimize care while reducing fragmentation and waste. Granted, substantial infrastructural challenges stand in the way, such as the inconsistent utilization of electronic medical records and the incompatibility of computer systems. 8 Furthermore, there are social hurdles such as attitude barriers, the lack of willingness to share care among providers 9 and the lack of consensus regarding best practice and the best methods of care. 7 Furthermore, the expectations of patients and health-care providers, in terms of their care, are often incongruent. 10 Such barriers are likely to have contributed to the redundant PSA testing observed by Skolarus et al. 1 in this study-a finding that could be further exacerbated by the various assays used in different labs, and the patients' desire for reassurance regarding their disease status. 7 Thus, there is a need, not only to increase communication among the various members of the healthcare team, but also to intimately include the patient in discussions regarding their own management. As the patient is likely to be keenly interested in their own healthcare coverage, any restrictions imposed by Medicare regarding payment for duplicate testing, with denial of benefit, could provide a powerful impetus to reduce redundant PSA testing and its associated costs. Overall, Skolarus and colleagues 1 provide solid, though not unexpected, information regarding the fragmentation of care among prostate cancer survivors. Whereas some degree of fragmentation can be reduced by encouraging survivors to seek a majority of their long-term care through their primary-care physicians, it is only through ensuring open lines of communica tion between health-care providers and entities that provide coverage as well as the patients themselves that we will have the best chance of optimizing care while reducing fragmentation.
